THE IMPACT OF CHRONIC CANNABINOID USE AND DEPENDENCE ON OPIOID ANALGESIC TREATMENT – A SYSTEMATIC REVIEW AND PREDICTIVE ANALYSIS
Abstract
In recent years, there has been growing interest in cannabinoids as potential analgesics and alternatives to opioids. Cannabinoids, through modulation of the endocannabinoid system, affect nerve transmission, neuroplasticity, and inflammatory processes, and their action on CB1 and CB2 receptors is similar to the mechanisms of the opioid system, in particular μ, δ, and κ receptors. The aim of this study was to compare the mechanisms of action of cannabinoids and opioids, review studies on their combined use, and assess the impact of chronic cannabinoid use and dependence on the effectiveness of opioid-based pain treatment.
Analysis of the available data showed that moderate use of cannabinoids, especially preparations with a balanced THC and CBD content, can lead to an "opioid-sparing" effect, allowing opioid doses to be reduced without losing the analgesic effect. However, chronic use of cannabinoids, especially those with high THC content, is associated with the development of tolerance, mood disorders, desensitization of CB1 receptors, and disturbances in the co-regulation of μ receptors, which may lead to compensatory escalation of opioid treatment and the development of cross-addiction. In addition, partial clinical benefits have been observed in patients with neuropathic pain from the combination of cannabinoid and opioid therapy, while no clear analgesic effects have been observed in acute pain.
The proposed predictive model integrates molecular, clinical, and psychological aspects, indicating that the effectiveness of analgesic therapy depends on the duration of exposure to cannabinoids, the type of pain, and the individual predisposition of the patient. The authors point to the need for further research involving patients who are chronic users of cannabinoids or addicted to them and who are scheduled to be treated with opioids. The results of such analyses could form the basis for the development of clinical guidelines for integrated pain therapy that minimizes the risk of addiction and treatment failure.
References
Bell, A. D., MacCallum, C., Margolese, S., Walsh, Z., Wright, P., Daeninck, P. J., Mandarino, E., Lacasse, G., Kaur Deol, J., de Freitas, L., St Pierre, M., Belle-Isle, L., Gagnon, M., Bevan, S., Sanchez, T., Arlt, S., Monahan-Ellison, M., O'Hara, J., Boivin, M., & Costiniuk, C. (2024). Clinical Practice Guidelines for Cannabis and Cannabinoid-Based Medicines in the Management of Chronic Pain and Co-Occurring Conditions. Cannabis and cannabinoid research, 9(2), 669–687. https://doi.org/10.1089/can.2021.0156
Schlag, A. K., Hindocha, C., Zafar, R., Nutt, D. J., & Curran, H. V. (2021). Cannabis based medicines and cannabis dependence: A critical review of issues and evidence. Journal of psychopharmacology (Oxford, England), 35(7), 773–785. https://doi.org/10.1177/0269881120986393
Kansagara, D., Hill, K. P., Yost, J., Humphrey, L. L., Shaw, B., Obley, A. J., Haeme, R., Akl, E. A., Qaseem, A., Population Health and Medical Science Committee of the American College of Physicians, Dunn, A. S., Jackson, C. D., Jokela, J. A., Lee, R. A., Mackey, K., Saini, S. D., Tschanz, M. P., Wilt, T. J., Etxeandia-Ikobaltzeta, I., Shamliyan, T., … Vigna, C. (2025). Cannabis or Cannabinoids for the Management of Chronic Noncancer Pain: Best Practice Advice From the American College of Physicians. Annals of internal medicine, 178(5), 714–724. https://doi.org/10.7326/ANNALS-24-03319
Marom, P., Novak, A. M., Heruti, R., & Lev-Ari, S. (2025). Enablers, Barriers and Practical Applications of a Group-Based Pain Self-Management Program for Patients Receiving Medical Cannabis: A Qualitative Study of Patients and Clinicians. Pain practice: the official journal of World Institute of Pain, 25(5), e70052. https://doi.org/10.1111/papr.70052
Sic, A., George, C., Gonzalez, D. F., Tseriotis, V.-S., & Knezevic, N. N. (2025). Cannabinoids in Chronic Pain: Clinical Outcomes, Adverse Effects and Legal Challenges. Neurology International, 17(9), 141. https://doi.org/10.3390/neurolint17090141
Shustorovich, A., Corroon, J., Wallace, M. S., & Sexton, M. (2024). Biphasic effects of cannabis and cannabinoid therapy on pain severity, anxiety, and sleep disturbance: a scoping review. Pain medicine (Malden, Mass.), 25(6), 387–399. https://doi.org/10.1093/pm/pnae004
Scavone, J. L., Sterling, R. C., & Van Bockstaele, E. J. (2013). Cannabinoid and opioid interactions: implications for opiate dependence and withdrawal. Neuroscience, 248, 637–654. https://doi.org/10.1016/j.neuroscience.2013.04.034
Ghosh, K., Zhang, G. F., Chen, H., Chen, S. R., & Pan, H. L. (2022). Cannabinoid CB2 receptors are upregulated via bivalent histone modifications and control primary afferent input to the spinal cord in neuropathic pain. The Journal of biological chemistry, 298(6), 101999. https://doi.org/10.1016/j.jbc.2022.101999
Johnson, B. W., Strand, N. H., Raynak, J. C., Jara, C., Habtegiorgis, K., Hand, B. A., Hong, S., & Maloney, J. A. (2025). Cannabinoids in Chronic Pain Management: A Review of the History, Efficacy, Applications, and Risks. Biomedicines, 13(3), 530. https://doi.org/10.3390/biomedicines13030530
Dagher, M., Alayoubi, M., Sigal, G. H., & Cahill, C. M. (2024). Unveiling the link between chronic pain and misuse of opioids and cannabis. Journal of neural transmission (Vienna, Austria: 1996), 131(5), 563–580. https://doi.org/10.1007/s00702-024-02765-3
Al-Husinat, L., Obeidat, S., Azzam, S., Al-Gwairy, Y., Obeidat, F., Al Sharie, S., Haddad, D., Haddad, F., Rekatsina, M., Leoni, M. L. G., & Varrassi, G. (2025). Role of Cannabis in the Management of Chronic Non-Cancer Pain: A Narrative Review. Clinics and practice, 15(1), 16. https://doi.org/10.3390/clinpract15010016
Ang, S. P., Sidharthan, S., Lai, W., Hussain, N., Patel, K. V., Gulati, A., Henry, O., Kaye, A. D., & Orhurhu, V. (2023). Cannabinoids as a Potential Alternative to Opioids in the Management of Various Pain Subtypes: Benefits, Limitations, and Risks. Pain and therapy, 12(2), 355–375. https://doi.org/10.1007/s40122-022-00465-y
Matos, C., Pereira, A. T., Dias, M. J., Sousa, C., Vinha, A. F., Moutinho, C., & Carvalho, M. (2025). Cannabis for Chronic Pain: Mechanistic Insights and Therapeutic Challenges. Stresses, 5(1), 7. https://doi.org/10.3390/stresses5010007
Botea, M. O., Andereggen, L., Urman, R. D., Luedi, M. M., & Romero, C. S. (2024). Cannabinoids for Acute Pain Management: Approaches and Rationale. Current pain and headache reports, 28(7), 681–689. https://doi.org/10.1007/s11916-024-01252-4
Davis M. P. (2016). Cannabinoids for Symptom Management and Cancer Therapy: The Evidence. Journal of the National Comprehensive Cancer Network: JNCCN, 14(7), 915–922. https://doi.org/10.6004/jnccn.2016.0094
Cortez-Resendiz, A., Leiter, T. J., Riela, S. M., Graziane, N. M., Raup-Konsavage, W. M., & Vrana, K. E. (2025). The Pharmacology of Cannabinoids in Chronic Pain. Medical cannabis and cannabinoids, 8(1), 31–46. https://doi.org/10.1159/000543813
Meccariello R. (2023). Molecular Advances on Cannabinoid and Endocannabinoid Research. International journal of molecular sciences, 24(16), 12760. https://doi.org/10.3390/ijms241612760
Urits, I., Charipova, K., Gress, K., Li, N., Berger, A. A., Cornett, E. M., Kassem, H., Ngo, A. L., Kaye, A. D., & Viswanath, O. (2021). Adverse Effects of Recreational and Medical Cannabis. Psychopharmacology bulletin, 51(1), 94–109. https://doi.org/10.64719/pb.4395
Kendall, D. A., & Yudowski, G. A. (2017). Cannabinoid Receptors in the Central Nervous System: Their Signaling and Roles in Disease. Frontiers in cellular neuroscience, 10, 294. https://doi.org/10.3389/fncel.2016.00294
Bushlin, I., Rozenfeld, R., & Devi, L. A. (2010). Cannabinoid-opioid interactions during neuropathic pain and analgesia. Current opinion in pharmacology, 10(1), 80–86. https://doi.org/10.1016/j.coph.2009.09.009
Pantoja-Ruiz, C., Restrepo-Jimenez, P., Castañeda-Cardona, C., Ferreirós, A., & Rosselli, D. (2022). Cannabis and pain: a scoping review. Brazilian journal of anesthesiology (Elsevier), 72(1), 142–151. https://doi.org/10.1016/j.bjane.2021.06.018
Oz, M., Yang, K. S., & Mahgoub, M. O. (2022). Effects of cannabinoids on ligand-gated ion channels. Frontiers in physiology, 13, 1041833. https://doi.org/10.3389/fphys.2022.1041833
Watkins A. R. (2019). Cannabinoid interactions with ion channels and receptors. Channels (Austin, Tex.), 13(1), 162–167. https://doi.org/10.1080/19336950.2019.1615824
Burggren, A. C., Shirazi, A., Ginder, N., & London, E. D. (2019). Cannabis effects on brain structure, function, and cognition: considerations for medical uses of cannabis and its derivatives. The American journal of drug and alcohol abuse, 45(6), 563–579. https://doi.org/10.1080/00952990.2019.1634086
Befort K. (2015). Interactions of the opioid and cannabinoid systems in reward: Insights from knockout studies. Frontiers in pharmacology, 6, 6. https://doi.org/10.3389/fphar.2015.00006
Le, K., Le, K. D. R., Nguyen, J., Hua, J., & Munday, S. (2024). The Role of Medicinal Cannabis as an Emerging Therapy for Opioid Use Disorder. Pain and therapy, 13(3), 435–455. https://doi.org/10.1007/s40122-024-00599-1
Toniolo, E. F., Gupta, A., Franciosi, A. C., Gomes, I., Devi, L. A., & Dale, C. S. (2022). Interactions between cannabinoid and opioid receptors in a mouse model of diabetic neuropathy. Pain, 163(7), 1414–1423. https://doi.org/10.1097/j.pain.0000000000002527
Carlin, V. E., LaRowe, L. R., & Ditre, J. W. (2025). Pain Intensity and Hazardous Cannabis Use: The Moderating Role of Pain-related Anxiety. Journal of psychoactive drugs, 1–8. Advance online publication. https://doi.org/10.1080/02791072.2025.2511756
Noori, A., Miroshnychenko, A., Shergill, Y., Ashoorion, V., Rehman, Y., Couban, R. J., Buckley, D. N., Thabane, L., Bhandari, M., Guyatt, G. H., Agoritsas, T., & Busse, J. W. (2021). Opioid-sparing effects of medical cannabis or cannabinoids for chronic pain: a systematic review and meta-analysis of randomised and observational studies. BMJ open, 11(7), e047717. https://doi.org/10.1136/bmjopen-2020-047717
Aviram, J., Lewitus, G. M., Vysotski, Y., Yellin, B., Berman, P., Shapira, A., & Meiri, D. (2021). Prolonged Medical Cannabis Treatment is Associated With Quality of Life Improvement and Reduction of Analgesic Medication Consumption in Chronic Pain Patients. Frontiers in pharmacology, 12, 613805. https://doi.org/10.3389/fphar.2021.613805
Karst M. (2024). Overview: Chronic Pain and Cannabis-Based Medicines. Pharmacopsychiatry, 57(3), 152–159. https://doi.org/10.1055/a-2231-6630
Ware, M. A., Wang, T., Shapiro, S., Collet, J. P., & COMPASS study team (2015). Cannabis for the Management of Pain: Assessment of Safety Study (COMPASS). The journal of pain, 16(12), 1233–1242. https://doi.org/10.1016/j.jpain.2015.07.014
Lucas, P., Boyd, S., Milloy, M. J., & Walsh, Z. (2021). Cannabis Significantly Reduces the Use of Prescription Opioids and Improves Quality of Life in Authorized Patients: Results of a Large Prospective Study. Pain medicine (Malden, Mass.), 22(3), 727–739. https://doi.org/10.1093/pm/pnaa396
Vázquez, M., Guevara, N., Maldonado, C., Guido, P. C., & Schaiquevich, P. (2020). Potential Pharmacokinetic Drug-Drug Interactions between Cannabinoids and Drugs Used for Chronic Pain. BioMed research international, 2020, 3902740. https://doi.org/10.1155/2020/3902740
Hoch, E., Volkow, N. D., Friemel, C. M., Lorenzetti, V., Freeman, T. P., & Hall, W. (2025). Cannabis, cannabinoids and health: a review of evidence on risks and medical benefits. European archives of psychiatry and clinical neuroscience, 275(2), 281–292. https://doi.org/10.1007/s00406-024-01880-2
Substance Abuse and Mental Health Services Administration (US), & Office of the Surgeon General (US). (2016). Facing Addiction in America: The Surgeon General's Report on Alcohol, Drugs, and Health. Washington (DC): U.S. Department of Health and Human Services.
Balestra, A. M., Chalk, K., Denke, C., Mohammed, N., Fritzsche, T., & Tafelski, S. (2023). Influence of Cannabinoid Treatment on Trajectories of Patient-Related Outcomes in Chronic Pain: Pain Intensity, Emotional Distress, Tolerability and Physical Disability. Brain sciences, 13(4), 680. https://doi.org/10.3390/brainsci13040680
Xu, K., Wu, Y., Tian, Z., Xu, Y., Wu, C., & Wang, Z. (2023). Microglial Cannabinoid CB2 Receptors in Pain Modulation. International journal of molecular sciences, 24(3), 2348. https://doi.org/10.3390/ijms24032348
Petzke, F., Tölle, T., Fitzcharles, M. A., & Häuser, W. (2022). Cannabis-Based Medicines and Medical Cannabis for Chronic Neuropathic Pain. CNS drugs, 36(1), 31–44. https://doi.org/10.1007/s40263-021-00879-w
Copyright (c) 2026 Tomasz Poczwardowski, Adrianna Kaczmarek, Franciszek Szweda, Kinga Augustyniak, Marcin Chwalczuk, Jakub Tomasz Latos, Olivia Grygorcewicz, Marta Koneczna, Katarzyna Anna Kowalska, Karolina Alicja Krystyniak
This work is licensed under a Creative Commons Attribution 4.0 International License.
All articles are published in open-access and licensed under a Creative Commons Attribution 4.0 International License (CC BY 4.0). Hence, authors retain copyright to the content of the articles.
CC BY 4.0 License allows content to be copied, adapted, displayed, distributed, re-published or otherwise re-used for any purpose including for adaptation and commercial use provided the content is attributed.
